Iron-loaded deferiprone can support full hemoglobinization of cultured red blood cells in the absence of transferrin
J. S. Gallego-Murillo, N. Yagcı, E. M. Pinho, A. Abeijon-Valle, A. Wahl, E. van den Akker, M. von Lindern
Abstract
Iron is an essential nutrient in mammalian cell cultures, conventionally supplemented as iron-loaded transferrin (holotransferrin). The high cost of human transferrin represents a challenge for the large scale production of cell therapies, such as cultured red blood cells. We evaluated the use of deferiprone, a cell membrane-permeable drug for iron chelation therapy, as an iron carrier for erythroid cultures. Iron-loaded deferiprone (Def3{middle dot}Fe3+) at a concentration of 52mol/L could fully replace holotransferrin during erythroblast differentiation into reticulocytes, the erythroid differentiation stage with maximal iron requirements. Reticulocytes cultured in presence of Def3{middle dot}Fe3+ or holotransferrin (1000g/mL) were similar with respect to expression of cell-surface markers CD235a and CD49d, hemoglobin content, and oxygen association/dissociation. Def3{middle dot}Fe3+ also supported expansion of the erythroid compartment in vitro, except for the first stage when hematopoietic stem cells committed to erythroblasts, in which a reduced erythroblasts yield was observed. This suggests that erythroblasts acquired the potential to process Def3{middle dot}Fe3+ as iron source for biosynthesis pathways. Replacement of holotransferrin by Def3{middle dot}Fe3+ was also successful in cultures of six myeloid cell lines (MOLM13, NB4, EOL1, K562, HL60, ML2). These results suggest that iron-loaded deferiprone can partially replace holotransferrin in chemically defined medium formulations for the production of cultured reticulocytes and proliferation of selected myeloid cell lines. This would lead to a significant decrease in medium cost that would improve the economic perspectives of the large scale production of red blood cells for transfusion purposes. Key pointsO_LIHolotransferrin limitations in erythroid cultures lead to lower erythroblast yields, impaired maturation and low enucleation efficiencies. C_LIO_LIIron-loaded deferiprone can replace holotransferrin in erythroblast expansion and differentiation cultures. C_LI
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- MNC-RED a Chemically Defined Method to Produce Enucleated Red Blood Cells from Adult Peripheral Blood Mononuclear Cells
S. E. Zhang, E. E. Olivier, … E. E. Bouhassira·bioRxiv·Apr 25, 2019
- Use of dual electron probes reveals role of ferritin in erythropoiesis
M. A. Aronova, S. J. Noh, … R. D. Leapman·bioRxiv·Dec 19, 2019
- Large-scale in-vitro production of red blood cells from human peripheral blood mononuclear cells
S. J. Heshusius, E. Heideveld, … E. M. van den Akker·bioRxiv·Jun 18, 2019
- Expansion and differentiation of ex vivo cultured erythroblasts in scalable stirred bioreactors
J. S. Gallego-Murillo, G. Iacono, … S. A. Wahl·bioRxiv·Feb 11, 2022
- Metabolic profiling of cultured erythroblast for the production of transfusion-ready cultured red blood cells
Joan Sebastián Gallego‐Murillo, Ingeborg van Lakwijk, … Emile van den Akker·bioRxiv·Jun 2, 2026
- Iron deficiency affects early stages of embryonic hematopoiesis but not the endothelial to hematopoietic transition
Maya Shvartsman, Saygın Bilican, Christophe Lancrin·Scientific ReportsPeer-reviewed·Apr 23, 2019